目的 探討艾迪注射液聯(lián)合雷替曲塞治療晚期結(jié)腸癌的有效性與安全性。方法 選取中國醫(yī)科大學(xué)附屬盛京醫(yī)院2016年3月-2017年3月收治的晚期結(jié)腸癌患者121例，隨機(jī)分成對照組（60例）和治療組（61例）。對照組患者靜脈滴注注射用雷替曲塞，3 mg/m²加入250 mL生理鹽水，1次/3周；治療組在對照組的基礎(chǔ)上靜脈滴注艾迪注射液，50 mL加入5%葡萄糖注射液400 mL，1次/d。兩組患者均治療9周。評價(jià)兩組患者臨床療效，同時比較治療前后兩組患者KPS評分、VAS評分、腫瘤標(biāo)志物水平和不良反應(yīng)情況。結(jié)果 治療后，對照組客觀緩解率和疾病控制率分別為43.33%、75.00%，均分別顯著低于治療組的63.93%、93.44%，兩組比較差異均具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者KPS評分明顯升高，VAS評分明顯降低，同組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組患者KPS和VAS評分改善情況明顯優(yōu)于對照組患者（P<0.05）。治療后，兩組患者癌胚抗原（CEA）和CA199水平均明顯下降（P<0.05）；且治療組患者CEA和CA199水平比對照組降低的更明顯（P<0.05）。治療組患者不良反應(yīng)發(fā)生率為21.31%，顯著低于對照組患者的50.00%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 艾迪注射液聯(lián)合雷替曲塞治療晚期結(jié)腸癌療效較好，安全性較高，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To explore the clinical effect and safety of Aidi injection combined with raltitrexed in treatment of advanced colorectal cancer. Methods Patients (121 cases) with advanced colorectal cancer in Shengjing Hospital of China Medical University from March 2016 to March 2017 were randomly divided into control (60 cases) and treatment (61 cases) groups. Patients in the control group were iv administered with Raltitrexed for injection, 3 mg/m² added into normal saline 250 mL, once every three weeks. Patients in the treatment group were iv administered with Aidi Injection on the basis of the control group, 50 mL added into 5% glucose injection 400 mL, once daily. Patients in two groups were treated for 9 weeks. After treatment, the clinical efficacy was evaluated, and the KPS and VAS scores, tumor marker level and adverse reactions in two groups before and after treatment were compared. Results After treatment, objective remission rate and disease control rate in the control group were 43.33% and 75.00%, which were significantly lower than 63.93% and 93.44% in the treatment group, respectively, and there were differences between two groups (P<0.05). After treatment, the KPS score in two groups was significantly increased, VAS score was significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the KPS and VAS scores in the treatment group were obviously better than those in the control group (P<0.05). After treatment, the CEA and CA199 levels in two groups were significantly decreased (P<0.05). And the CEA and CA199 levels in the treatment group were obviously lower than that in the control group (P<0.05). During the treatment, the incidence of adverse reactions in the control group was 50.00%, which were significantly higher than 21.31% in the control group, with significant difference between two groups (P<0.05). Conclusion Aidi Injection combined with raltitrexed has perfect curative effect and high safety in treatment of advanced colorectal cancer, which has a certain clinical application value.